CYP2D6

Cytochrome P450 2D6 · P10635 · CYP2D6 on Sugi Atlas →

1,859,030 patent compounds predicted against CYP2D6, 1,151,548 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Mizolastine (SCHEMBL5061)	0.75	17/20
Indinavir Anhydrous (SCHEMBL6317)	0.75	13/20
Chlorpromazine (SCHEMBL8321)	1.00	9/20
SCHEMBL2407	0.65	8/20
SCHEMBL4305	0.63	8/20
Promethazine (SCHEMBL4700)	1.00	7/20
Propranolol (SCHEMBL3955)	1.00	6/20
Levopropranolol (SCHEMBL3956)	1.00	6/20
Ritonavir (SCHEMBL6679)	1.00	6/20
Bicuculline (SCHEMBL8222)	1.00	6/20
Fluconazole (SCHEMBL3151)	0.53	6/20
Miconazole (SCHEMBL2866)	1.00	5/20
(R)-Miconazole (SCHEMBL2867)	1.00	5/20
Procaine (SCHEMBL3524)	1.00	5/20
Fasudil (SCHEMBL4674)	1.00	5/20
Amitriptyline (SCHEMBL7824)	1.00	5/20
Miconazole (SCHEMBL3366)	0.98	5/20
(R)-Miconazole (SCHEMBL3367)	0.98	5/20
Chloroprocaine (SCHEMBL6676)	0.67	5/20
Dicyclomine (SCHEMBL3317)	1.00	4/20

Clinical trials — most relevant to CYP2D6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Combined Analgesia to Control Pain in Children Seen in Emergency Department (ED) for a Trauma of a Limb	PHASE4	COMPLETED
The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine	PHASE4	WITHDRAWN
Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.	PHASE3	COMPLETED
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	PHASE2	WITHDRAWN
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer	PHASE2	COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients	PHASE2	COMPLETED
Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol	PHASE1	COMPLETED
Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults	PHASE1	COMPLETED
Bioequivalence Trial of a New Opioid Combination Compared to Reference	PHASE1	COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan	PHASE1	COMPLETED
Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients	PHASE1	UNKNOWN
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone	PHASE1	UNKNOWN
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients	PHASE1	COMPLETED
Genetic Variability in CYP2D6 in U.S Active Duty Population	PHASE1	COMPLETED
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000	PHASE1	COMPLETED
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects	PHASE1	COMPLETED
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults	EARLY_PHASE1	NOT_YET_RECRUITING
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy	nan	UNKNOWN
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Distribution of CYP2D6 Multiplication, CYP2D6*5, and Clinical Implications in Postoperative Patients Receiving Tramadol Analgesia in the Minangkabau Ethnic Group, Indonesia	nan	COMPLETED
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
CYP2B6 Polymorphisms in Methadone Disposition	nan	COMPLETED
CYP2D6 Polymorphism in Patients of General Practice in Austria	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2D6 binder may also engage these)

Protein	Name	Similarity
Q29488	—	1.000	Q29488 →
Q2XNC8	—	1.000	Q2XNC8 →
O18992	—	1.000	O18992 →
Q64403	—	1.000	Q64403 →
Q64680	—	1.000	Q64680 →
Q29473	—	1.000	Q29473 →
Q01361	—	1.000	Q01361 →
A0A087X1C5	—	1.000	A0A087X1C5 →
Q9QUJ1	—	1.000	Q9QUJ1 →
Q2XNC9	—	0.999	Q2XNC9 →
Q9QYG5	—	0.998	Q9QYG5 →
O46658	—	0.997	O46658 →
Q9QYG6	—	0.996	Q9QYG6 →
P24456	—	0.995	P24456 →
P11714	—	0.995	P11714 →
P10633	—	0.995	P10633 →
P12938	—	0.993	P12938 →
P12939	—	0.993	P12939 →
P10634	—	0.990	P10634 →
E9Q816	—	0.990	E9Q816 →
P24457	—	0.990	P24457 →
Q8CIM7	—	0.986	Q8CIM7 →
Q4V8D1	—	0.986	Q4V8D1 →
Q9DBX6	—	0.985	Q9DBX6 →
Q9CX98	—	0.984	Q9CX98 →
Q8WNW0	—	0.983	Q8WNW0 →
CYP2W1	Cytochrome P450 2W1	0.983	landscape →
CYP2J2	Cytochrome P450 2J2	0.982	landscape →
P15540	—	0.981	P15540 →
CYP21A2	Steroid 21-hydroxylase	0.981	landscape →